Clinical efficacy and safety of lymphocyte apheresis combined with plasma exchange in the treatment of patients with hepatitis B virus-related liver failure at the ascending stage

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059146

Enrollment

Unknown

Registered

2022-04-26

Start date

2016-04-01

Completion date

Unknown

Last updated

2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Failure

Interventions

Experimental group:lymphocyte apheresis combined with plasmapheresis

Control group:conservative medical treatment

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years; 2. HBsAg (+) for more than six months; 3. The increase of TBIL was > 17umol/L/ day (more than three days); 4. 20% =400U/L or AST>=400U/L; 6. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Liver damage combined with other causes, such as drugs, alcohol, other viral hepatitis, etc.; 2. Patients with malignant tumor; 3. Complicated with hepatic encephalopathy, hepatorenal syndrome and severe infection; 4. Those with unstable circulation; 5. Patients with active bleeding.

Design outcomes

Primary

Measure	Time frame
The ratio of clinical improvement;	—

Secondary

Measure	Time frame
Model for end-stage liver disease (MELD) score;	—

Countries

China

Contacts

Public ContactGao Hongbo

Guangzhou Eighth People's Hospital

gz8hghb@126.com+86 13711263989

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026